Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
Top Growth Stocks To Follow Now – March 7th
Blackstone, BlackRock, Apollo Global Management, Novo Nordisk A/S, Welltower, Prologis, and Venture Global are the seven Growth stocks to watch today, according to MarketBeat’s stock screener tool.
Growth Stocks To Watch Now – March 6th
Blackstone, BlackRock, and Novo Nordisk A/S are the three Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of companies that are expected to grow ...
Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
Notable healthcare headlines for the week: Walgreens Boots Alliance, AbbVie and Novo Nordisk in focus
Wall Street's major averages dipped for the week as investors wrestled with tariff twists from the Trump administration. The ...
Shocking stories of people who went blind after taking Ozempic and Mounjaro
Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...
To see what European business could become, look to the Nordics
The rest of Europe could learn from them. Politicians in Brussels are perpetually searching for ways to invigorate the ...
pharmaphorum23h
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...